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Abstract
Introduction: Type 1 diabetes (T1D) is characterized by autoimmune-induced dysfunction and 
destruction of the pancreatic beta cells. Unfortunately, this process is poorly understood, and the 
current best treatment for type 1 diabetes is administration of exogenous insulin. To better 
understand these mechanisms and to develop new therapies, there is an urgent need for biomarkers 
that can reliably predict disease stage.
Areas covered: Mass spectrometry (MS)-based proteomics and complementary techniques play 
an important role in understanding the autoimmune response, inflammation and beta-cell death. 
MS is also a leading technology for the identification of biomarkers. This, and the technical 
difficulties and new technologies that provide opportunities to characterize small amounts of 
sample in great depth and to analyze large sample cohorts will be discussed in this review.
Expert opinion: Understanding disease mechanisms and the discovery of disease-associated 
biomarkers are highly interconnected goals. Ideal biomarkers would be molecules specific to the 
different stages of the disease process that are released from beta cells to the bloodstream. 
However, such molecules are likely present in trace amounts in the blood due to the small number 
of pancreatic beta cells in the human body and the heterogeneity of the target organ and disease 
process.
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1.0 Introduction
Type 1 diabetes (T1D) is caused by immune-mediated dysfunction and destruction of 
insulin-producing β cells, resulting in chronic hyperglycemia and the lifelong need for 
exogenous insulin therapy. Histological analysis of donor pancreases from T1D patients, 
together with measurements of serum C-peptide in clinical cohorts, suggests that many 
patients with clinical T1D still have a sub-population of surviving but non-functional β cells 
[1]. T1D develops from a complex “dialogue” that is established between invading immune 
cells, which release a variety of chemokines and cytokines, and putative immunogenic 
signals released by injured or dying β cells [2]. This dialogue is shaped by a number of 
factors, including host genetic architecture, key clinical/demographic features such as age 
and the “exposome” [3], which includes viral infections, dietary components, environmental 
exposures, and others [4]. In susceptible individuals, the integration of these factors leads to 
triggering of an autoimmune assault against the pancreatic β cells that provokes local 
inflammation (insulitis) and progressive β-cell loss mostly due to apoptosis [2,4,5].
The prevalence of T1D is doubling every 25 years in children in many places around the 
globe [6,7], and persons affected by the disease lose around 12 years of life expectancy 
[8,9]. The Centers for Disease Control and Prevention (CDC) reports that T1D is the third 
most prevalent chronic disease of childhood in the USA, behind asthma and obesity (CDC, 
2018). For the purposes of clinical trials and immune intervention, a staging classification 
system has been introduced that defines Stage 1 as a state of normoglycemia in the presence 
of β-cell autoimmunity (two or more autoantibodies), Stage 2 as a state of dysglycemia (but 
not overt diabetes) in the presence of β-cell autoimmunity, and Stage 3 as overt, 
symptomatic T1D [10]. Most of the past clinical trials have been initiated at the onset of 
Stage 3 T1D, which is a time associated with substantial loss of functional β-cell mass. To 
date, 6 different drugs have shown efficacy in delaying the loss of C-peptide secretion, when 
administered at Stage 3 onset. These include: 1) a monoclonal antibody against the B cell 
CD20 receptor (rituximab); 2) a monoclonal antibody against the T cell CD3 receptor 
(teplizumab); 3) CTLA4-lg-mediated co-stimulatory blockade with abatacept, 4) alefacept, 
which is a fusion protein that binds CD2 and targets CD4+ and CD8+ effector memory T 
cells [11,12], 5) imatinib, a tyrosine kinase inhibitor; and 6) low-dose anti-thymocyte 
globulin (ATG), which is a polyclonal IgG against T cells [13]. While these trials met their 
primary endpoint, defined as an improvement in insulin secretion in response to a nutrient 
challenge, the vast majority of treated individuals still required insulin therapy. In part, this 
could be because drugs were initiated too late in the disease process. Indeed, a recently 
completed trial of teplizumab in Stage 2 disease supported this concept and showed that 
teplizumab treatment was able to delay the onset of Stage 3 disease on average by 2 years 
[14].
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Despite promising results of these clinical trials, no drug has yet been FDA-approved as a 
disease-modifying therapy for T1D. This gap in translating trial results into clinical practice 
is multifactorial and includes: 1) a continued lack of understanding of the heterogeneous 
molecular mechanisms that trigger and drive the autoimmune destruction of human β cells 
and 2) a lack of sufficiently accurate genetic or molecular biomarkers of disease progression 
that could enable the introduction of immunomodulatory therapies at a time prior to the 
irreversible damage of β cells and that can serve as “sentinels” to the fate of these β cells 
during the course of these interventions. In this context, mass spectrometry (MS)-based 
proteomics is playing a central role in elucidating pathogenic mechanisms of autoimmune 
destruction of β cells and in identifying new biomarkers of the disease. This review will 
focus on MS-based, bottom-up proteomics workflows, which typically consist of several 
steps, including protein extraction, enzymatic digestion, separations (e.g. strong cation 
exchange (SCX) or reversed-phase (RP) chromatography) at protein or peptide levels, liquid 
chromatography–tandem mass spectrometry (LC-MS/MS) analyses, and bioinformatics data 
analysis and interpretation. Such approaches have enabled deep profiling of proteomes (e.g., 
quantification of > 10,000 proteins) with great dynamic range [15]. Metabolic labeling 
strategies such as stable isotope labeling by amino acids in cell culture (SILAC) [16] or 
isobaric labeling methods such as tandem mass tags (TMT) [17] can be incorporated into 
this workflow to facilitate quantitative analysis. Besides isobaric labeling, label-free 
approaches have also been broadly utilized in MS-based proteomics [18]. A summary of the 
key techniques used in the field is listed in Table 1.
Here, we provide a summary of the current knowledge on the etiology and pathophysiology 
of T1D, recent work in biomarker development, and the potential of MS-based proteomics 
and other complementary technologies for advancing the understanding of β-cell 
dysfunction and the discovery of T1D biomarkers.
2.0 Autoantigens and the autoimmune response in T1D
Immune activation in type 1 diabetes is thought to be first initiated by the presentation of β-
cell peptides by antigen presenting cells (APCs) (Figure 1), but the initiating event(s) in this 
process remain to be discovered. These APCs migrate to the pancreatic lymph nodes, where 
they interact with autoreactive CD4+ T cells. CD4+ T cells mediate the activation of 
autoreactive CD8+ T lymphocytes cells, which are ultimately responsible for the lysis of β 
cells expressing immunogenic self-antigens on MHC class I surface molecules. Autoreactive 
CD4+ T cells within the pancreatic lymph node also stimulate B lymphocytes to produce 
autoantibodies against β-cell proteins. These autoantibodies are considered to be defining 
biomarkers of T1D [4].
How immune tolerance is overcome and by which processes novel antigens (neoantigens) 
appear are still not well understood. Proteomics approaches can be instrumental in 
identifying key neoantigens, although these have been underutilized in T1D research. 
Peptides presented by cells can be co-purified by immunoprecipation of the MHC molecules 
(i.e. the “HLA ligandome”) and analyzed by LC-MS/MS in an approach known as 
“immunopeptidomics” [19,20]. Immunopeptidomics has been demonstrated in cell cultures, 
human islets and thymic and splenic tissues of non-obese diabetic mice [21,22]. Importantly, 
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these studies showed that the peptides presented can change substantially when cells are 
stimulated with pro-inflammatory cytokines [21,22], which could be a source of neoantigen 
formation. Neoantigens can result from alternative splicing (AS) [23], formation of hybrid 
peptides [24], or via protein post-translational modifications (PTMs) [25,26]. AS is a 
complex post-transcriptional mechanism that regulates gene expression and generates 
protein diversity. By modulating the inclusion of different exon combinations into the pre-
mRNA, AS allows individual genes to produce structurally distinct mRNA and protein 
isoforms with different biological functions [23]. Alternative exons can also introduce 
premature stop codons, regulating mRNA levels through degradation by the nonsense-
mediated decay [27]. More than 90% of human genes undergo AS [28], with an enormous 
variation between cell types, developmental stage, stimuli and disease. Peptides derived 
from AS can be detected in human islets and they were shown to be reactive to CD8+ T 
cells, reinforcing the idea that AS is an important process that leads to autoimmunity [22].
Hybrid peptides are also known as spliced peptides and are formed by transpeptidation 
reactions (ligation of peptides from different proteins) by the proteasome [29]. A large 
immunopeptidomics survey has shown that these hybrid peptides comprise approximately 
30% of all peptides presented by MHC class I molecules [30]. Hybrid peptides have also 
been detected in human and murine pancreatic islets by MS-based proteomics analysis 
[22,31]. Hybrid insulin peptides are indeed recognized by pathogenic CD4+ T cells, 
suggesting that this could be a mechanism leading to immunotolerance breakage [24,31].
PTMs are also an increasingly recognized mechanism to produce potential β-cell-specific 
neoantigens [25,26,32]. The inflammation or stress in the islet microenvironment could 
create unique conditions for β cells to produce various PTMs. For example, increased levels 
of reactive oxygen species (ROS), calcium dyshomeostasis, activation of inducible nitric 
oxide synthase (iNOS), as well as activation of tissue transglutaminase (tTG) and 
peptidylarginine deiminase (PAD), have all been reported in islets during inflammation 
[33-35]. Such conditions lead to the production of tissue specific PTMs. For instance, 
deamination of arginine residues into citrulline on glucose-regulated protein 78 (GRP78/
Bip) is induced by PAD upon treatment of rat INS-1E β-cell line in a proteomics 
experiment. Importantly, citrullinated GRP78 is recognized by effector T cells, showing that 
this PTM is also a possible candidate for inducing autoimmune response [36,37].
3.0 Role of inflammation in the pathogenesis of β-cell death in T1D
During early immune cell infiltration into the pancreatic islet (insulitis), inflammation 
contributes both to the primary induction and secondary amplification of the immune 
assault, and inflammatory mediators trigger functional suppression and apoptosis of β cells 
(Figure 2) [2]. This inflammation takes place as part of the dialogue between invading 
immune cells and the target β cells. This dialogue is mediated by cytokines/chemokines 
released by β cells and immune cells and by putative immunogenic signals delivered by 
dying or “altered” β cells. Progressive loss of β-cell mass is the key central feature of T1D, 
and immune cells contribute to β-cell apoptosis by cell-to-cell interactions, via the Fas-FasL 
and perforin-granzyme systems, and by local release of pro-inflammatory cytokines [2]. 
Different cytokines affect β cells at different stages of the disease. For example, interferon-α 
Nakayasu et al. Page 4













(IFN- α) plays a crucial role during early stages of insulitis, and signaling downstream of 
IFN-α induces long-lasting HLA class I expression, endoplasmic reticulum (ER) stress (see 
below) and chemokine production [38,39], all potential contributors to insulitis and β-cell 
damage. On the other hand, IFN-α also induces the expression of key β-cell defense 
mechanisms against the immune attack, particularly PDL1 expression [40]. Interleukin-1β 
(IL-1β), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and interleukin-17 (IL-17) 
are released at later stages of the autoimmune assault by the infiltrating macrophages and T-
cells, contributing to β-cell dysfunction and death [2]. Cytokine-induced β-cell apoptosis is 
highly dependent on the activation of complex gene networks regulated by transcription 
factors (TFs) such as NF-κB [41,42] and STAT-1 [42].
Proteomic analysis of a rat INS-1E cell line showed that IL-1β and IFN-γ regulate a large 
number of proteins related to insulin secretion, cytoskeleton organization, RNA metabolism, 
and ER and oxidative stress [43]. To better understand the mechanisms of cytokine-mediated 
regulation of β cells, Ramos-Rodriguez and colleagues performed a comprehensive multi-
omics analysis of human islets and the human EndoC-βH1 cell line treated with the 
combination of IL-1β + IFN-γ, and integrated the resulting data. The measurements 
included proteomics, chromatin immunoprecipitation followed by DNA sequencing (ChIP-
Seq), DNA methylation analysis, assay for transposase-accessible chromatin sequencing 
(ATAC-seq), transcriptomics (RNA-seq) and genome-wise association study (GWAS). Such 
combination of techniques enabled the investigation of how cytokines promote chemical and 
physical changes in the structure of the chromatin, and whether these changes are associated 
with genomic loci with higher risk of T1D and with consequent changes in mRNA and 
protein expression [44]. The study found two loci in genomic regions that are regulated by 
cytokines: rs78037977 in the region of the cytokine gene TNFSF18, and rs193778 in the 
region of the DEXI gene, which was shown to participate in β-cell death via cytokine 
signaling [45]. Importantly, the polymorphism in these loci was shown to have a strong 
effect in the expression of the respective genes [44].
Viral infections from Enteroviruses have been proposed as one mechanism through which 
autoimmunity is triggered [46]. A proteomics study of human islets infected in vitro with 
Coxsackievirus B4 showed a strong immune response associated with type I interferon 
signaling, which is consistent with the expression of cytokines and other antiviral response 
factors [47]. In agreement with these observations, transcriptomics analyses of human islets 
exposed to the pro-inflammatory cytokines IL-1β + IFN-γ, or infected with Coxsackievirus 
B5, showed similar expression patterns [48]. Despite similarities in the response to cytokines 
and viral infections in whole islets, α and β cells individually showed important differences 
in response to Coxsackievirus infections. Coxsackievirus 5 infection induced massive 
apoptosis in FACS-sorted rat β cells but not in α cells [48]. This may be explained by the 
higher expression of innate immunity/antiviral proteins in α cells compared to β cells [48], 
suggesting that α cells are better equipped to fight the viral infection, whereas β cells are 
unable clear the virus and eventually undergo apoptosis. These findings can provide an 
explanation on the selective death of β cells during T1D development.
PTMs, such as protein phosphorylation, acetylation, ubiquitination and methylation, are also 
of significant interest for gaining detailed mechanistic understanding of cellular processes 
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during insulitis and cell death. Despite its importance, comprehensive PTM analyses by 
mass spectrometry have been poorly explored in studying β-cell death, primarily due to the 
limited sensitivity of typical PTM workflows. To date, most studies were carried out with 
cell lines or samples from mouse models. For example, Engholm-Keller et al. identified 
~6,600 unique phosphopeptides from the insulin-secreting rat INS-cell line [49]. Several 
studies reported the phosphoproteome dynamics during glucose-stimulated insulin secretion 
(GSIS) using rat and mouse pancreatic islets by implementing TiO2 enrichment and LC-
MS/MS [50-52]. In the case of β-cell death, Palmisano et al treated the rat insulinoma cell 
line NHI 6F Tu28 with the pro-inflammatory cytokines IL-1β + TNFα and performed 
phosphoproteomic and glycoproteomic analysis of extracellular vesicles secreted by these 
cells [53]. This analysis showed regulation of PTMs on proteins related to cell signaling. 
Furthermore, such modifications were upregulated in proteins related to cell death and 
downregulated in cell morphology proteins [53]. A major hurdle for a more systematic 
analysis of islet PTMs is the large amounts of material (typically milligrams of peptides) 
required for enriching modified peptides. More recently, Yi et al. reported a “boosting to 
amplify signal with isobaric labeling (BASIL)” strategy for quantitative phosphoproteome 
profiling in small cell populations [54]. They further demonstrated a pilot study of 
examining the phosphoproteome changes of human islets treated by IL-1β and IFN-γ for 24 
h where a comprehensive coverage of ~25,000 phosphopeptides was achieved. The observed 
alterations of phosphorylation were involved in a number of previously reported pathways 
such as interferon and cytokine signaling, and antigen processing and presentation. The 
continual advances for of more sensitive techniques for PTM analysis should have an 
immediate impact in further elucidating the mechanisms underlining the insulitis and β-cell 
death processes.
4.0 Potential roles of endoplasmic reticulum stress in insulitis
One potentially important mechanism by which pro-inflammatory signaling contributes to 
β-cell death and amplification of inflammation in T1D is via induction of endoplasmic 
reticulum (ER) stress, and the consequent triggering of the Unfolded Protein Response 
(UPR) [55,56]. The UPR is mediated through activation of three ER transmembrane 
proteins: inositol-requiring protein 1α (IRE1α), protein kinase RNA-like endoplasmic 
reticulum kinase (PERK) and activating transcription factor 6 (ATF6). These proteins sense 
the accumulation of unfolded proteins in the ER lumen and activate mechanisms to restore 
its homeostasis. In case of unresolved ER stress, persistent stimulation of the UPR triggers 
apoptosis via activation of C/EBP homologous protein (CHOP), c-jun N-terminal kinase 
(JNK), death protein 5 (DP5) and other pro-apoptotic signals [57]. Consistent with these 
observations, proteomic analysis of the rat INS-1E cell line treated with IL-1β + IFN-γ 
showed a regulation of ER stress response [43]. A subsequent study in INS-1E cells using 
the ER stress inducer cyclopiazonic acid showed that ER stress induces massive apoptosis 
[58], linking the cytokine-induced ER stress response and UPR to cell death [55,56]. The 
same study also showed that ER stress has a major impact in expression, processing and 
release of insulin [58]. A key component of the UPR system, GRP78 protein, was shown to 
be regulated in islets from non-obese diabetic mice (NOD), a mouse model of autoimmune 
diabetes, in the prediabetic stage [59], indicating that a similar ER stress response occurs in 
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vivo. Moreover, a GWAS analysis showed that mutations on the GATA4 transcription factor 
resulted in increased expression of UPR proteins in association with T1D occurrence [60].
Importantly, in both NOD mice and in T1D individuals, the β cells express markers of ER 
stress [61-63], but eventually fail to sustain key components of the adaptive UPR [62]. This 
contributes to their eventual demise. Activation of ER stress may also lead to presentation of 
neoantigens through the generation of aberrant or modified proteins that escape central 
tolerance [26,36,64-66]. Upon ER stress induction, alternative initiation sites can be used 
during translation of insulin mRNA and generate highly immunogenic insulin gene-derived 
polypeptides targeted by T-cell autoreactivity in individuals with T1D [67]. Induction of the 
UPR was shown also to impact on calcium-dependent enzymes that induce post-translational 
changes, such as tTG2 and PAD [33,35], leading to the production of neoantigens as 
described above.
Despite the advances in knowledge described above, the precise mechanisms by which 
autoimmunity is triggered and aggravated in T1D remain poorly understood, and the 
regulatory networks and signaling events that promote β-cell dysfunction and death or lead 
to protection remain to be clarified.
5.0 Linking pathways of β-cell dysfunction to biomarker development
Most clinical trials in T1D have been initiated at the onset of Stage 3 T1D. As the success of 
this approach has been modest, an alternative is to intervene earlier in the disease process, at 
a time when greater β-cell mass remains. Whilst the presence of multiple autoantibodies 
signifies future risk of developing T1D, the time-frame of disease development is unclear 
based on the measurement of autoantibody status alone. Furthermore, determination of these 
autoantibodies neither allows evaluation of progressive cell death nor of the potential impact 
of novel therapies to protect them. Thus, the idea of developing biomarkers of β-cell stress 
and death is attractive and offers the potential of both targeting the individuals at highest risk 
and evaluating the effects of intervention therapies. However, a major challenge is to 
discriminate the signals emitted from insulitis and the dying β cells, as β cells comprise only 
1-2% of the pancreas mass (1-2 g total in humans), from signals emitted by other tissues. 
Moreover, T1D poses a unique challenge owing to the relative inaccessibility of the target 
organ for interrogation by imaging or biopsy in living individuals.
Several studies have identified markers of β-cell dysfunction and new onset of T1D in 
human urine and blood plasma or serum [68-71]. A proteomic analysis of urine from 
children with T1D showed a consistent increase of several lysosomal enzymes [72], which 
was validated in a second cohort [73]. Release of lysosomal enzymes is a process associated 
with inflammation, which in this case could be a consequence of the damage to the renal 
tubular epithelial cells caused by chronic hyperglycemia [72,73]. Proteins related to 
inflammation and other innate immune response processes are commonly found as blood 
biomarkers of islet autoimmunity and T1D onset [68-71]. While a number of biomarker 
candidates have been reported from recent literature [74], most of them are present in 
plasma in mid to high abundances, but not necessarily being directly derived from β cells. 
The extremely low abundance of proteins specific to pancreatic islet cells and the 
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heterogeneity of disease make the discovery of new biomarkers more challenging. To 
aggravate this scenario, blood plasma is one of the most challenging sample types for 
proteomics analysis due to the presence of highly abundant proteins, with 12 of the most 
abundant proteins comprising more than 95% of the total mass [75]. LC-MS/MS analysis of 
whole, normal human plasma typically leads to the detection of less than 400 proteins 
[76,77]. However, this number can be increased to ~2,000 with immunodepletion of the 
most abundant proteins together with peptide fractionation prior to the LC-MS/MS analysis 
[78]. The challenge in this case is the significant labor and instrument time required which 
typically prevents the analysis of large cohorts of samples. One way to circumvent this issue 
is to design the study in two phases, a “discovery” phase where deep proteomic analysis on a 
limited number of samples is performed, followed by a “validation” phase using a targeted 
proteomics approach. Targeted proteomics is limited in the number of proteins that can be 
measured in a single measurement - up to ~200 proteins - but it can be used to analyze large 
sample cohorts with high sensitivity (as low as 10 pg/mL range), since, depending on the 
concentration of protein targets, immunodepletion may not be required, and the overall 
analytical analysis time can be significantly shortened [79]. This discovery/validation 
approach was applied to analyze plasma from patients with new onset T1D and led to the 
discovery of platelet basic protein and C1 inhibitor as biomarkers [68]. The recent advances 
in mass spectrometry and proteomics technologies, increasing the sensitivity and throughput 
of measurements (see below), will have a major role to enable precise quantification of islet-
derived proteins in plasma from large sample cohorts.
Measurement of serum insulin and C-peptide can provide insight into T1D risk [80,81] and 
impaired insulin secretion may be present as early as five years before disease onset [82]. 
However, measurement of C-peptide is typically performed in the context of glucose or 
mixed-meal stimulation, which requires fasting and multiple blood draws after nutrient 
ingestion. An indicator of β-cell dysfunction and ER stress is the delayed conversion of 
proinsulin to insulin [61], measurable as the proinsulin to C-peptide or insulin ratio. In this 
regard, fasting proinsulin/C-peptide ratios were found to be elevated 12 months in advance 
of diabetes diagnosis and predicted T1D risk [83]. Recently, proinsulin secretion was found 
to persist in persons with long-standing T1D, even in those who were functionally C-peptide 
negative [84]. A second secreted prohormone, β cell-derived pro-islet amyloid polypeptide 
(pro-IAPP) relative to total IAPP, was found to be similarly elevated in children with 
longstanding type 1 diabetes [85], suggesting that impaired prohormone processing may be 
an important component of T1D pathophysiology as well as a potential source of novel 
biomarkers.
MicroRNAs (miRNAs) are small non-coding RNAs that have been found to play a central 
role in the regulation of gene expression. Along these lines, several miRNAs have been 
shown to play a role in T1D pathogenesis [86-88]. Compared to mRNA species, miRNAs 
are highly stable in biological fluids, where they have been detected in high abundance in 
blood, urine, saliva, cerebrospinal fluid, milk, seminal fluid, and amniotic fluid [89]. 
Analysis of sera from individuals with established T1D or autoantibody-positivity has 
identified a number of differentially expressed miRNAs, several of which were correlated 
with indices of β-cell function [90,91]. Although miRNAs are of intracellular origin, they 
may also be packaged into microvesicles or exosomes and release of vesicle-associated 
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miRNAs may increase under disease conditions. A recent study showed that T lymphocyte 
derived miRNAs can be transferred to the β cell in models of T1D, where these miRNAs 
were found to impact β-cell survival [92]. Pro-inflammatory cytokines increased both β cell 
miR-21-5p expression and its packaging into exosomes. Moreover, exosomal-associated 
miR-21-5p was increased in sera of pediatric subjects with recent onset T1D as compared to 
non-diabetic controls [93]. Similarly, differences in exosome-derived miRNA signatures 
have also been demonstrated in long-duration T1D [94].
Exosomes may also serve as a source of protein biomarkers in T1D. Proteomics and 
immunoblot analysis identified several autoantigens in human islet and rat-islet derived 
exosomes, including proinsulin, GAD65, and IA-2. Furthermore, cytokine treatment was 
found to increase markers of ER stress in exosomes [95]. Indeed, glypican 1-containing 
exosomes has been described as a potential biomarker for pancreatic cancer [96]. Therefore, 
exosomes have the potential to lead to the discovery of biomarkers for T1D as well. A key 
challenge in translating these ex vivo findings is the development of techniques that allow 
for the isolation and analysis of β cell-derived exosomes found in trace amounts in serum or 
plasma, for instance by “fishing” them based on the expression of cell [97,98] or islet 
specific proteins [97]. Furthermore, new advances in microfluidic exosome isolation 
[99,100] coupled to nanoscale proteomics sample preparation (see below) may provide 
sufficient sensitivity and specificity, opening new opportunities to explore exosomes as 
sources of T1D biomarkers.
Other nucleic acid species have also been proposed to serve as biomarkers of early β-cell 
stress and death. Cell-free DNA in the circulation is thought to arise largely from dead or 
dying cells, since release of cellular DNA, unlike miRNAs, does not occur routinely in living 
cells. The premise of interrogating cell-free DNA is based on the concept that stable, 
epigenetic modifications of DNA (such as cytosine methylation) can vary from one cell type 
to another within a given organism. Some genes expressed largely or exclusively in the β 
cell, such as the gene encoding insulin (INS), are unmethylated at cytosines, whereas they 
are methylated in virtually every other cell type. Using bisulfite chemistry and PCR, several 
groups have demonstrated increased unmethylated INS DNA in the circulation of NOD mice 
just prior to T1D development and in humans at the onset of T1D [101-103]. Notably, it has 
been demonstrated that unmethylated INS in the circulation can be detected in individuals 
prior to the onset of overt T1D, suggesting that β-cell death precedes the onset of T1D [104]. 
Other β cell-specific genes have been similarly developed as biomarkers, including IAPP 
and GCK [105,106]. Whereas cell-free DNAs may represent very sensitive biomarkers 
owing to the high sensitivity of PCR methodologies, they nevertheless pose other significant 
limitations, including lack of cell-type specificity and their inability to report on cell stress 
(only death).
6.0 Advanced MS technologies provide new perspectives on studying T1D 
progression
Particular challenges associated with proteomics studies of pancreatic β cells, islets, or 
clinical samples (e.g. plasma), are the need for high sensitivity in the analytical approaches 
Nakayasu et al. Page 9













due to the limited amounts of material available, especially for primary mouse or human 
tissues or cells; the need for a high measurement dynamic range in order to accurately 
quantify both high and low abundance proteins, the latter of which may be among the most 
interesting biomarker candidates; and the need for high throughput in order to have the 
capacity for screening samples from large study cohorts. High measurement sensitivity can 
also enable direct proteome characterization of clinical specimens such as islet cells isolated 
by laser-capture microdissection (LCM) at near single-cell level.
An important area of recent advance is nanoscale proteomics for effective analyses of small 
populations of cells (e.g., <5000 cells). One of the first related reports was the analysis of 
freshly harvested single mouse pancreatic islets containing 2,000–4,000 cells by Waanders 
et al [107]. Although proteomics of fixed tissue is challenging, due to the cross-linking 
process, the analysis of 13,000-30,000 cells laser-capture microdissected from human islets 
led to the identification of 1,100-2,000 proteins [108,109]. More recently, it was described 
an online processing system described as a simplified nano-proteomics platform (SNaPP), 
which consisted of an online immobilized enzyme reactor digestion system and a solid phase 
extraction (SPE) column coupled with a nanoLC separation system [110]. SNaPP was 
applied for proteome profiling for as few as 500 mouse lung alveolar cells isolated by LCM 
[111]. Several other single tube-based approaches were also reported for analyzing small 
populations of cells, such as the trifluoroethanol-based approach [112], focused 
ultrasonication [113], and the integrated proteome analysis device (iPAD) [114].
Despite these advances, it remains challenging to achieve robust analysis of extremely small 
cell populations (e.g., <500 cells). Li and colleagues used a microfluidic reaction chamber 
for proteomics analysis of a single HeLa cell, identifying 51 proteins [115], while Budnik et 
al. recently used a carrier cell approach to minimize the non-specific sample losses that 
frequently occur in analyses of single cells due to binding to tubes and columns during 
sample preparation [116]. It has been recently reported the development of the nanoPOTS 
(Nanodroplet Processing in One-pot for Trace Samples) platform for enabling robust 
proteomics measurements of 10-100 cells [117]. By coupling this with laser microdissection, 
this novel platform enabled quantitative proteome profiling of single human islet sections 
(10 μm in thickness, ~100 cells), resulting in the quantitative detection of ~2,400 proteins 
(Figure 3). Significant differences in abundances of 304 proteins were observed between 
T1D and control islets based on single islet proteomics, including drastic reduction of the 
abundances of β cell-specific proteins such as insulin and PCSK1, and increased abundances 
of immune-responsive proteins such as β−2-microglobulin and HLA-class I antigens (Figure 
3). Importantly, nanoPOTS opens opportunities for investigating the underlying molecular 
mechanisms of islet inter- and intra-individual heterogeneity [118] by performing 
measurements at single islet levels. Furthermore, the nanoPOTS platform also enabled deep 
proteome profiling for <1000 cells or ~10 islet sections from an AAb+ donor with >6,300 
islet proteins being identified, including low abundance transcription factors such as PDX1 
and NKX 2.2 [119].
To address current analytical limitations in measurement dynamic range and overall study 
throughput for MS-based proteomics, ion mobility (IM) separations are increasingly 
incorporated into laboratory workflows. IM instruments separate molecules in the gas-phase 
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based on their charge state, size and shape, as influenced by their chemical makeup and 
spatial structure of the molecule. IM separations typically occur on the scale of milliseconds, 
allowing them to be “nested” between LC (minutes to hours) and MS (microseconds) 
dimensions [120]. Thus, integrating IM into LC-MS-based proteomics workflows can 
potentially provide greater coverage of sample proteomes by increasing the dynamic range 
of the measurement through addition of an additional dimension of separation, or can allow 
for decreasing LC separation times while maintaining the same measurement coverage and 
thereby increasing overall analysis throughput [120].
Although the incorporation of IM measurements into routine molecular analysis workflows 
is still emerging, there have been several very promising developments recently that should 
facilitate protein biomarker discovery and validation efforts. Zhang et al. reported on the 
development of an automated SPE-IM-MS platform for analysis of metabolites that required 
less than 1 minute per sample and that allowed a theoretical throughput of 8,000 analyses 
per day (Figure 4) [121]. The implementation of this platform in high throughput proteomics 
analyses of large clinical cohorts would provide a long sought after solution for population-
scale proteomics analyses. Meier and colleagues recently developed a data acquisition 
method called parallel accumulation - serial fragmentation (PASEF), using trapped-IM 
integrated with LC-MS. The PASEF approach enabled an unprecedented 600,000 
fragmentation spectra to be collected using a standard 120-minute LC separation, identifying 
>6,000 proteins in a single analysis of a HeLa cell protein digest. In terms of sensitivity, 
PASEF resulted in the identification of >2,500 proteins in a 30-minute analysis of 10 ng of 
HeLa digest [122]. A next generation IM device – structures for lossless ion manipulations 
(SLIM) – has been developed and should provide resolving powers much higher than 
traditional IM instruments, comparable to those provided by traditional LC separations 
[123]. In a recent, intriguing study, Dou et al. coupled nanoPOTS with SLIM in analysis of a 
HeLa protein digest; the combined LC-SLIM IM separation peak capacity was ~3600 or 
over ~18-fold higher than that for LC-MS alone [124].
Mass cytometry is another recently developed technique for high throughput analysis of 
samples in single cell resolution. In mass cytometry, proteins/markers of interest are targeted 
by antibodies labeled with metals. These metals are then detected by highly sensitive 
inductively coupled plasma-mass spectrometry (ICP-MS). Unlike fluorophores that usually 
have a broad spectrum of emission, metals have discrete masses, consequently increasing the 
resolution and avoiding overlapping readings. This allows to track more than 35 cellular 
markers simultaneously, enabling the resolution of cell type subpopulations [125]. Mass 
cytometry can be either coupled to flow cytometry to measure cell populations or used to 
obtain images of sliced tissue [125,126]. Both techniques have been applied to characterize 
human islets. Mass cytometry coupled to flow cytometry has been applied to characterize 
different populations of endocrine cells in the islets of healthy, non-diabetic individuals 
[127]. The results showed that the β-cell population is on average 65% of the islets in 
children, but it is reduced to approximately 42% in adults. This analysis also showed that 
there were two subpopulations of proliferating β cells that combined represented 4% of the 
total population in an 18-day old baby but were reduced to almost zero in adults [127]. The 
very low proliferation rate of β cells observed in older children and adults is in line with 
previous observations based on other methods [128] and highlights the importance of 
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developing novel approaches to prevent β-cell loss in T1D. Mass cytometry has also been 
used to track immune cells in individuals with insulitis, which identified subpopulations of 
regulatory T cells and natural killer cells that are increased during islet autoimmunity [129]. 
Besides those cell types, some aberrant lymphocytes containing characteristics of both B and 
T cells, have been very recently identified in T1D patients [130]. This novel immune cell 
type might have a key role in autoimmunity, but these intriguing observations must be 
confirmed by additional studies.
Compared to flow cytometry, imaging mass cytometry has the advantage of providing spatial 
resolution, which allows to study intra-individual variability between islets and to determine 
immune cell populations infiltrated in islets. Recent studies also showed recruitment of 
cytotoxic and helper T cells into the islets in individuals with T1D [131,132]. These papers 
also showed intra-individual variation in endocrine cell population in islets when comparing 
the head and tail of the pancreas [131,132]. Previous analyses of pancreata from individuals 
with T1D using traditional histologic approaches have shown geographic variability in the 
persistence of β cells (reviewed in [1]). These results highlight a potential heterogeneity in 
the susceptibility of some populations of β cells to immune-mediated destruction. Overall, 
novel techniques such as nanoPOTS, IM-MS and mass cytometry have tremendously 
enhanced the sensitivity and throughput of MS-based omics measurements. These 
technologies are likely to play a major role in obtaining a better understanding of the 
molecular mechanisms behind T1D development and the identification of associated protein 
biomarkers.
7.0 Conclusions
MS-based proteomics is playing a central role in elucidating mechanisms of autoimmune 
response, insulitis, and β-cell death, leading to the identification of new biomarkers for T1D. 
We are presently facing a situation where T1D can be predicted with good accuracy via 
determination of circulating autoantibodies and where understanding of the disease is 
improving. However, this has not yet translated into novel therapies that can prevent or 
revert the disease. The recent developments in MS-based proteomics techniques and 
instrumentation have resulted in significant improvements in the sensitivity and throughput 
of sample analysis, which opens new opportunities for better understanding the T1D 
pathogenesis and for discovering and validating novel biomarkers.
8.0 Expert opinion
Understanding the pathways that lead to β-cell dysfunction and death in T1D are crucial for 
the discovery of circulating biomarkers that can be monitored during the initiation and 
amplification of insulitis and the progressive -cell death. For this purpose, it will be 
necessary to measure both information that “spills” from stressed/dying cells and released 
factors (i.e., exosomes, cytokines and hormones) into the circulation as a result of the above-
described dialog between the immune system and cells. It is indeed a major challenge to 
discriminate the signals emitted from insulitis and the dying cells – cells comprise only 
1-2% of the pancreas volume and an average total weight of 1-2 g – as compared to other 
autoimmune diseases with strong inflammatory components that affect much larger amounts 
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of tissue, such as rheumatoid arthritis or inflammatory bowel disease. To achieve this goal, 
we must keep in mind the question “what is unique to T1D”? The answer is the specific 
destruction of pancreatic cells by the immune system. We must thus focus first and foremost 
on the mechanisms leading to autoimmunity, insulitis and -cell apoptosis, identify locally 
produced/released biomarkers, and then search for them in the circulation.
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• Biomarkers that can accurately predict the early stages of type 1 diabetes are 
urgently needed to improve our knowledge about the disease mechanism and 
to develop new therapies.
• Proteomics analysis has provided insights to islet autoimmunity and 
inflammation, as well as signaling events and regulated processes in type 1 
diabetes.
• Immunopeptidomics analyses contributed to the discovery of auto-reactive 
neoantigens present in type 1 diabetes.
• Post-translationally modified and hybrid peptides are targets of the 
autoimmune response during type 1 diabetes development.
• Nanoproteomics and mass cytometry analyses have enabled to study in great 
detail the intra- and inter-individual islet variability and immune cell 
infiltration in islets during insulitis.
• Emerging technologies, such as ion mobility spectrometry, will have a major 
role in identifying new biomarkers and better understanding of the disease.
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Figure 1. Type 1 Diabetes Pathogenesis.
During the development of Type 1 diabetes, antigen-presenting cells (APCs) residing within 
the pancreas process and present β-cell peptides on MHC class I molecules. APCs bearing 
these peptides travel to the pancreatic lymph nodes, where they initiate an immune response 
that includes activation of autoreactive CD8 T cells and autoantibody production by B 
lymphocytes. Pancreatic β cells expressing immunogenic peptides on MHC class I surface 
molecules are targeted for destruction by autoreactive CD8 T cells. Cells of the innate 
immune system (macrophages, natural killer cells, and neutrophils) exacerbate β-cell death 
and inflammation through local release of cytokines, chemokines, and reactive oxygen 
species. β cells participate in this process by releasing chemokines and by up-regulating 
MHC class I molecules and the associated machinery for antigen presentation. The immune 
reaction is amplified by impairments in the ability of T regulatory cells to effectively 
suppress autoimmunity. Autoantibodies against β cells are important markers of immune 
activation but are not known to play a direct role in disease pathogenesis. Reprinted from 
The Lancet, Vol. 391, DiMeglio LA, Evans-Molina C, Oram RA, Type 1 diabetes, Pages 
2449-2462, Copyright (2018) [4], with permission from Elsevier.
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Figure 2. The dialogue between pancreatic β cells and the immune system that leads to induction 
and amplification of insulitis and the transition between innate and adaptive immune responses.
Recognition of endogenous and exogenous “danger signals” by PRRs (TRL3/4, RIG-1, 
MDA5) lead to activation of key transcription factors such as NF-κB, IRF1, IRF3 and 
STATs (stimulatory of inflammatory signaling) and JunB (inhibitory). Activation of these 
transcription factors will induce: 1. release of several chemokines promoting attraction and 
activation of immune cells; 2. increase β-cell expression of MHC class I which, associated 
with ER stress and changes in AS, lead to presentation of modified antigens to the immune 
cells; 3. activation of pro-apoptotic signals leading to β-cell death. Products of dying β cells 
are taken by professional antigen-presenting cells (dendritic cells) contributing for activation 
of auto-reactive T-cells. During this local inflammatory process, known as insulitis, pro-
inflammatory cytokines such as IFN-α (early stage) or IL-1β, IL-17, TNF-α and IFN-γ 
(later stages) are released by the immune cells and induce transcription factors such as 
STAT-1, STAT-2 NF-κB and IRF-1 in the β cells contributing either for the maintenance and 
amplification of the networks described above, or, in some cases, to down-regulation of 
immunity via activation of PDL1 and other T-cell inhibitory signals. If insulitis is not 
resolved, it will result in a progressive and selective destruction of pancreatic β cells. 
Abbreviations: AS, alternative splicing; ER, endoplasmic reticulum; IFN, interferon; IL, 
interleukin; PRR, pattern-recognition receptor; TLR, Toll-like receptor; TNF, tumor necrosis 
factor. Reprinted by permission from: Springer Nature, Nature Reviews Endocrinology, The 
role of inflammation in insulitis and β-cell loss in type 1 diabetes, Eizirik DL, Colli ML, 
Ortis F, Copyright 2009 [2].
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Figure 3. nanoPOTS-enabled proteomics analysis of single human pancreatic islet sections.
a) Overview of the nanoPOTs workflow (scale bar is 500 μm), b) reproducibility of protein 
abundances in nine human islet sections from a non-diabetic donor as represented by 
pairwise correlations, c) islet protein expression differences between a non-diabetic donor 
and a donor with T1D, based on nanoPOTS-based proteomics measurements of single islets. 
Reproduced from Zhu et al. [117] under a Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/).
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Figure 4. Ultra-high throughput molecular analyses using SPE-IM-MS.
Samples are bulk separated using SPE, followed by analysis using IM-MS. Each SPE-IM-
MS analysis requires just 10-seconds. Reproduced from Zhang et al. [121] under a Creative 
Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/
4.0/).
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Table 1
Key proteomics techniques used for studying type 1 diabetes.
Technique Brief description Applications References
Global shotgun proteomics In global shotgun proteomics, samples are 
digested with proteases, most often trypsin, and 
the resulting peptides are analyzed by one- or 
two-dimensional LC-MS/MS. Peptides are 
identified through database search algorithms 
and the proteins are then inferred.
This technique is used to determine the 
global landscape of expressed proteins. 
It can be used to obtain semi-
quantitative information of expressed 
proteins, peptides and post-translational 
modifications.
[15]
Isotopic labeling Proteins and peptides can be labeled with amino 
acids or chemical groups containing stable, 
heavy isotopes. This labeling can be done in cell 
culture (SILAC – stable isotope labeling of 
amino acids in cell culture), in vivo or during 
sample processing.
The incorporation of heavy isotopes 
provides a mass shift, without altering 
other physical-chemical properties of 
peptides. Therefore, heavy labeled 
peptides have the same ionization 
efficiency and signal in the mass 
spectrometer, allowing samples to be 
multiplexed for quantitative proteomic 
analysis.
[16,133]
Isobaric chemical labeling In isobaric chemical labeling, proteins or 
peptides are derivatized with chemical reagents 
(tandem mass tags – TMT, or isobaric tags for 
relative and absolute quantitation – iTRAQ) 
which incorporate a combination of heavy 
isotopes that provide the same intact mass. Upon 
tandem mass fragmentation of the labeled 
peptides, reporter ions of different masses are 
generated and facilitate peptide quantification.
Isobaric labeling is used for quantitative 
analysis. Commercially available kits 
allow to label and multiplex up to 11 
samples into single analysis.
[17]
Targeted proteomics In targeted proteomics, specific peptides are 
measured by selected-reaction monitoring using 
triple quadrupole mass spectrometers. Peptides 
of interest are selected in the first quadrupole, 
fragmented in the second and specific fragments 
are filtered for detection in the third quadrupole. 
This procedure drastically reduces the chemical 
background, allowing to detect trace amounts of 
samples. Targets are usually compared against 
heavy isotope-labeled peptides used as internal 
standards, resulting in accurate measurements of 
the analytes.
Precise quantification of specific 
proteins, peptides or post-translational 
modifications. This technique is 
especially powerful for validating 
targets identified by global proteomics.
[134]
Immunopeptidomics or HLA 
ligandome
In this approach peptides that are being 
presented by major histocompatibility molecules 
(MHC) are captured by immunoaffinity 
purification and analyzed by liquid 
chromatography-tandem mass spectrometry.
Determine the pool of antigens being 
presented by the organism to the 
immune system.
[19,20]
Immunodepletion Highly abundant proteins from biofluids 
captured from samples with immunoaffinity 
columns. This reduces the overwhelming signals 
of the highly abundant proteins in the mass 
spectrometer, improving the detection of low 
abundant proteins.
Immunodepletion is a key step for deep 
proteomic analysis of samples, such as 
human blood plasma, in which the top 
12 proteins represents approximately 
95% of the protein mass.
[75,135]
Laser-capture microdissection Regions of sliced tissues are precisely cut with 
laser.
Proteomic analysis of specific regions of 
tissues, such as the islets of Langerhans.
[136]
Nanoproteomics Proteomic analysis performed in nanoscale 
(nanoliters of volume) to prevent sample loss.
Proteomic analysis of small samples, 
such as sorted cell populations or single 
cells.
[110,117]
Ion mobility spectrometry Ion mobility spectrometry is a technique used to 
separate ionized molecules based on their 
mobility in an inert buffer gas under an electric 
field. In this technique molecules are separated 
by charge, size and shape.
This technique can separate isobaric 
molecules, allowing to characterize 
isomers. The separation also decreases 
the chemical background, enhancing the 
detection of analytes. Due to its 
separation speed, it allows samples to be 
analyzed in seconds, enabling analysis 
of thousands of samples in a single day.
[120]
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Technique Brief description Applications References
Mass cytometry In mass cytometry, cells or tissues are stained 
with metal-labeled antibodies, which are 
detected by inductively coupled plasma mass 
spectrometry.
Mass cytometry coupled to flow 
cytometry is especially powerful to 
determine subpopulations of cells. 
Imaging mass cytometry provides 
spatial resolution, allowing to determine 
the distribution of different cells in 
tissues.
[125,126]
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